Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation [Seeking Alpha]
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Seeking Alpha
The resolution to the leverage issues lies in divesting Bausch + Lomb Corp shares, which could bring in much-needed cash to reduce debt. The divestiture could result in an upside potential of around 40% for Bausch Health. Bausch Health ( NYSE: BHC ) is a high-quality pharmaceutical company that has shown great resiliency and ability to innovate. However, it is also loaded with an expensive and heavy debt load of more than $20 billion that is weighing on the equity valuation. The key to resolving the leverage issues remains the complete or substantial divestiture of the Bausch+Lomb Corp shares. This would bring much-needed cash to reduce debt and increase the chances for a stock valuation re-rate. We believe that after the divestiture, there is an upside potential of around 40%. A snapshot: leverage, cash flows, and products portfolio Bausch Health is a highly diversified business with 4+1 segments, if we include the Bausch+Lomb partnership. The four core divisions of the st
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry EyesBusiness Wire
- Bausch + Lomb Co. (NYSE: BLCO) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $18.00. They now have an "outperform" rating on the stock.MarketBeat
- Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs [Yahoo! Finance]Yahoo! Finance
BLCO
Earnings
- 2/21/24 - Beat
BLCO
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/2/24 - Form 4
- BLCO's page on the SEC website